No Data
No Data
Express News | Lexicon Pharmaceuticals Presents Findings On The Burdens Of Diabetic Peripheral Neuropathic Pain Among 3 Sponsored Presentations At The 84th Scientific Sessions Of The American Diabetes Association
Even After Rising 8.0% This Past Week, Lexicon Pharmaceuticals (NASDAQ:LXRX) Shareholders Are Still Down 69% Over the Past Five Years
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly. For example the Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) share price dropped 69%
Lexicon Pharmaceuticals (NASDAQ:LXRX) Adds US$51m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 69%
Piper Sandler Reaffirms Their Buy Rating on Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced its participation in the Jefferies Global Healthcare Conference. Jeff Wade, Lexicon's president and
No Data